Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The inhibition of SGLT2 improves hyperglycemia hampering urinary reabsorption of glucose and inducing glycosuria
Reconstitution Considerations: Due to N-terminal lipidation , complete dissolution may require gentle vortexing or brief sonication
After discontinuation, there was a pronounced rebound in weight (MD = 4.13 kg, 95% CI: 1.60 to 6.65), BMI (MD = 0.84 kg/m 2 , 95% CI: 0.37 to 1.32), WC (MD = 3.64 cm, 95% CI: 2.27 to 5.01), and HbA1c (SMD = 0.69, 95% CI: 0.50 to 0.89)
The GLP-1 receptor agonist market is still primarily anchored in type 2 diabetes management, where these drugs improve glycemic control, reduce HbA1c levels, and mitigate cardiovascular risks
